Faron Pharmaceuticals - Company & Market Research Reports

Faron pharmaceuticals was founded in 2003 in Turku, Finland. It is a clinical stage drug discovery and development company. The company focuses on acute organ traumas, vascular damage, and cancer immunotherapy. Faron pharma is most well known for Traumakine, to prevent vascular leakage and organ failures, is currently the only treatment for Acute Respiratory Distress Syndrome (ARDS) undergoing Phase III clinical trials. It also develops Clevegen, a preclinical immunotherapy candidate, designed to prevent tumor growth and metastasis that targets the tumor immune suppressor molecule.

From
From
From
From
From
From
From
From
Ovarian Cancer - Pipeline Review, H1 2018 - Product Thumbnail Image

Ovarian Cancer - Pipeline Review, H1 2018

  • Drug Pipelines
  • 2412 Pages
From
Pancreatic Cancer - Pipeline Review, H1 2018 - Product Thumbnail Image

Pancreatic Cancer - Pipeline Review, H1 2018

  • Drug Pipelines
  • 2509 Pages
From
From
Melanoma - Pipeline Review, H1 2018 - Product Thumbnail Image

Melanoma - Pipeline Review, H1 2018

  • Drug Pipelines
  • 2011 Pages
From
From
From
From
From
From
Competitor Analysis: Interferon - Product Thumbnail Image

Competitor Analysis: Interferon

  • Report
  • 89 Pages
From
From
Faron Pharmaceuticals Oy - Product Thumbnail Image

Faron Pharmaceuticals Oy

  • Company Profile
  • 72 Pages
Loading Indicator
adroll